Pharma’s $130B M&A Comeback, China’s Innovation Rise, Healthcare’s Third-Party Risk

Good morning, ! This week the pharma’s innovation map is being redrawn. China is rapidly closing the new-drug launch gap with the U.S., biopharma M&A hit $130B in just six months, and healthcare providers are discovering that their biggest cyber risks may sit outside their own walls.

Know someone who would love this? Pass it along—they’ll thank you later! Here’s the link.

Join PE150 and Caplink for our AI & Data Insight Breakfast in London. Register here.

DATA DIVE

Innovation Is Going Global

Pharma's innovation engine is producing more new medicines — but where those drugs are reaching patients is changing fast.

According to IQVIA, 388 novel active substances (NAS) were launched globally between 2021 and 2025, up from 289 during the previous five-year period. The U.S. remains the leading individual market, with roughly 270 launches, but China has undergone the most dramatic transformation: from fewer than 90 launches in 2011–2015 to more than 260 in 2021–2025, bringing it close to U.S. levels. Europe and Japan have grown more gradually, widening the gap with the two largest markets.

Why it matters: New-drug commercialization is becoming increasingly multipolar. For Pharma, China is no longer simply a large end-market; its growing access to novel medicines strengthens its position in global launch strategies, licensing decisions and ultimately the economics of where innovation gets monetized.

Read more

HEALTHTECH CORNER

Healthcare’s Third Party Problem

Healthcare’s cyber exposure increasingly sits outside the four walls of the provider. According to Omega Systems, 85% of surveyed practices experienced at least one operational disruption caused by a third party over the past 12 months. More concerning, 24% reported 3 to 5 disruptions, while another 6% experienced 6 to 10.

The implication is that vendor risk is becoming operational risk. As practices rely on more cloud platforms, billing systems, EHR integrations, and other technology partners, resilience increasingly depends on infrastructure they do not directly control.

For healthtech vendors, that raises the bar. Security credentials alone are not enough. Buyers have a reason to scrutinize business continuity, incident response, redundancy, and vendor dependencies before signing contracts.

Why it matters: For operators and investors, third party resilience is becoming part of the product itself. In a market where vendor failures can interrupt care delivery, reliability can become a competitive advantage rather than simply a compliance requirement. (More)

PRESENTED BY CAPLINK X PE 150

You’re invited: Where AI Meets Private Equity

Artificial intelligence has moved beyond experimentation. The real question for private equity firms is no longer whether to adopt AI, but how to turn it into measurable value across the investment lifecycle.

On November 18, PE150 and CapLink Group will host the AI / Data & Insight Private Capital Breakfast, an invitation-only gathering at London's May Fair Hotel that will bring together operating partners, deal teams, portfolio executives, and technology leaders to discuss what AI adoption actually looks like inside private equity.

The morning will feature three practitioner-led discussions:

• AI Into Value Creation — How leading firms are transforming AI from dashboards into repeatable value creation playbooks across portfolio companies.

• AI Across the Investment Lifecycle — Practical applications spanning sourcing, due diligence, investment decisions, and portfolio management.

• Building the AI-Enabled Private Equity Firm — The operating models, data strategies, and organizational capabilities required to scale AI successfully.

Interested in attending? Register or request the full agenda here.

Interested in sponsoring? Email [email protected] 

COMPETITIVE LANDSCAPE SNAPSHOT

TREND TO WATCH

Biopharma M&A Is Accelerating Again

Biopharma dealmaking has moved decisively back into expansion. In the first half of 2026 alone, total M&A value reached $130 billion, nearly matching the $133 billion recorded across all of 2025 and already exceeding full-year totals in 2021, 2022 and 2024.

The acceleration is visible not only in headline value, but also in transaction intensity. Forty-two deals were announced in 1H26, compared with 50 during all of 2025, while average deal size climbed to $3.1 billion, up from $2.7 billion last year.

The pattern suggests large pharmaceutical companies are becoming more willing to deploy capital to replenish pipelines, secure differentiated assets and offset looming patent expirations. Importantly, the recovery appears broader than a handful of mega-deals.

For investors, the key question is whether this momentum persists into 2027—and whether increased competition for high-quality biotech assets begins to push acquisition multiples materially higher. (More)

INTERESTING ARTICLES